Literature DB >> 14560928

Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.

Hongjian Zhang1, Ming Yao, Richard A Morrison, Saeho Chong.   

Abstract

Tween 80 (Polysorbate 80) is a hydrophilic nonionic surfactant commonly used as an ingredient in dosing vehicles for pre-clinical in vivo studies (e.g., pharmacokinetic studies, etc.). Tween 80 increased apical to basolateral permeability of digoxin in Caco-2 cells suggesting that Tween 80 is an in vitro inhibitor of P-gp. The overall objective of the present study was to investigate whether an inhibition of P-gp by Tween 80 can potentially influence in vivo absorption of P-gp substrates by evaluating the effect of Tween 80 on the disposition of digoxin (a model P-gp substrate with minimum metabolism) after oral administration in rats. Rats were dosed orally with digoxin (0.2 mg/kg) formulated in ethanol (40%, v/v) and saline mixture with and without Tween 80 (1 or 10%, v/v). Digoxin oral AUC increased 30 and 61% when dosed in 1% and 10% Tween 80, respectively, compared to control (P < 0.05). To further examine whether the increase in digoxin AUC after oral administration of Tween 80 is due, in part, to a systemic inhibition of digoxin excretion in addition to an inhibition of P-gp in the GI tract, a separate group of rats received digoxin intravenously (0.2 mg/kg) and Tween 80 (10% v/v) orally. No significant changes in digoxin IV AUC was noted when Tween 80 was administered orally. In conclusion, Tween 80 significantly increased digoxin AUC and Cmax after oral administration, and the increased AUC is likely to be due to an inhibition of P-gp in the gut (i.e., improved absorption). Therefore, Tween 80 is likely to improve systemic exposure of P-gp substrates after oral administration. Comparing AUC after oral administration with and without Tween 80 may be a viable strategy in evaluating whether oral absorption of P-gp substrates is potentially limited by P-gp in the gut.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14560928     DOI: 10.1007/bf02976689

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  30 in total

Review 1.  Absorption enhancers: applications and advances.

Authors:  Bruce J Aungst
Journal:  AAPS J       Date:  2011-11-22       Impact factor: 4.009

2.  Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates.

Authors:  Huadong Sun; K Sandy Pang
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

3.  PS80 interferes with the antiallergic effect of Cry-consensus peptide, a novel recombinant peptide for immunotherapy of Japanese cedar pollinosis, at very low concentration through modulation of Th1/Th2 balance.

Authors:  Daisuke Kozutsumi; Masako Tsunematsu; Taketo Yamaji; Rika Murakami; Minehiko Yokoyama; Kohsuke Kino
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

4.  Evidences for anti-mycobacterium activities of lipids and surfactants.

Authors:  Afzal Hussain; Sandeep Kumar Singh
Journal:  World J Microbiol Biotechnol       Date:  2015-12-28       Impact factor: 3.312

5.  Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol.

Authors:  Anna Elgart; Irina Cherniakov; Yanir Aldouby; Abraham J Domb; Amnon Hoffman
Journal:  Pharm Res       Date:  2013-05-18       Impact factor: 4.200

6.  Influence of intestinal efflux pumps on the absorption and transport of furosemide.

Authors:  Abdullah M Al-Mohizea
Journal:  Saudi Pharm J       Date:  2010-02-13       Impact factor: 4.330

7.  Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.

Authors:  Naveed Shaik; Guoyu Pan; William F Elmquist
Journal:  J Pharm Sci       Date:  2008-12       Impact factor: 3.534

Review 8.  Polymers influencing transportability profile of drug.

Authors:  Vinod L Gaikwad; Manish S Bhatia
Journal:  Saudi Pharm J       Date:  2013-10       Impact factor: 4.330

9.  Efficacy and Pharmacokinetic Considerations of Loratadine Nanoformulations and its Combinations for Pancreatic Cancer Chemoprevention.

Authors:  Preshita Desai; Kevin Zhijun Wang; David Ann; Jeffrey Wang; Sunil Prabhu
Journal:  Pharm Res       Date:  2020-01-02       Impact factor: 4.200

10.  Starch Nanoparticles for Enhancement of Oral Bioavailability of a Newly Synthesized Thienopyrimidine Derivative with Anti-Proliferative Activity Against Pancreatic Cancer.

Authors:  Ahmed R Gardouh; Ahmed S G Srag El-Din; Mohamed S H Salem; Yasser Moustafa; Shadeed Gad
Journal:  Drug Des Devel Ther       Date:  2021-07-16       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.